Shenyang Xingqi Pharmaceutical Co.,Ltd.

300573

CNE100002DV1

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2026-04-21			5-day change	1st Jan Change
66.30 ^CNY	-1.31%		-3.07%	-5.68%

04-21	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-12	Shenyang Xingqi Pharmaceutical Doses First Patient in Eye Drop Trial	MT

Xingqi Pharmaceutical Gets Nod for Supplementary Application for Atropine Sulfate Eye Drops

Published on 01/05/2026 at 02:19 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shenyang Xingqi Pharmaceutical Co.,Ltd.

04-21	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-12	Shenyang Xingqi Pharmaceutical Doses First Patient in Eye Drop Trial	MT
03-10	Xingqi Pharmaceutical Completes Establishment of New Subsidiary	MT
01-05	Xingqi Pharmaceutical Gets Nod for Supplementary Application for Atropine Sulfate Eye Drops	MT
12-08	Xingqi Pharmaceutical's 39 Products Stay in China's Insurance Drug Catalogue	MT
25-10-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-09	Shenyang Xingqi Pharmaceutical Gets China Clinical Trial Nod for Macular Edema Injection	MT
25-09-16	Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Interim Cash Dividend on A Shares for 2025, Payable on 24 September 2025	CI
25-08-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Cash Dividend for the Year 2025	CI
25-08-27	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-06-17	Xingqi Pharmaceutical Begins Phase Three Trial for Anesthetic Gel	MT
25-05-30	Xingqi Pharmaceutical Says No Adverse Effects Seen in Phase 1 Eye Drops Trial	MT
25-05-26	Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 850 million in funding	CI
25-05-15	Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Final Cash Dividend Plan on A Shares for 2024, Payable on 22 May 2025	CI
25-04-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

Chart Shenyang Xingqi Pharmaceutical Co.,Ltd.

Duration

Period

Chart Shenyang Xingqi Pharmaceutical Co.,Ltd.

300573: Dynamic Chart

SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Companyâ€™s main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.

Employees

2,426

Sector

Pharmaceuticals

Calendar

03:00am - Earnings release - Annual 2025

More about the company